Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1

Published:2024-03 Issue: Volume:201 Page:107091
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Tao Li,Xia Xiangyu,Kong Shujing,Wang Tingye,Fan Fangtian,Wang Weimin

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference56 articles.

1. State-of-the-art strategies for targeting the DNA damage response in cancer;Pilie;Nat. Rev. Clin. Oncol.,2019

2. DNA repair defects in cancer and therapeutic opportunities;Hopkins;Genes Dev.,2022

3. BRCA1/2 testing: therapeutic implications for breast cancer management;Tung;Br. J. Cancer,2018

4. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA;Risdon;Oncologist,2021

5. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers;Pilie;Clin. Cancer Res,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies;Pharmaceuticals;2024-04-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP